Back grey arrow rt.gif
 
 
Cipla to market MSD's HIV drug 'raltegravir' in India
 
 
  The drug majors also announced an India specific strategic partnership
 
Press Trust of India | New Delhi February 20, 2014

 
Drug majors Cipla and MSD today announced an India specific strategic partnership under which the former will have a non-exclusive license to market, promote and distribute MSD's 'raltegravir' 400 mg tablet, an HIV drug, under a different brand name, in the country.
 
MSD is the trade name of US-based Merck & Co, Inc. It operates its business in India through three separate legal entities: MSD Pharmaceuticals, Organon (India) Pvt Ltd, and Fulford (India) Ltd.
 
"Access to treatment and patient centric approach are cornerstone to this partnership. With this model both firms expect to broaden reach of raltegravir in private and public markets in India," the two companies said in a joint statement.
 
Commenting on the development, MSD in India Managing Director K G Ananthakrishnan said the partnership is aligned with the company's commitment towards patients in India.
 
"It is a complementary partnership as MSD brings the research and scientific excellence for raltegravir and Cipla brings their marketing excellence, significant reach among key clinician categories to drive product access," he added.
 
Cipla Chief Medical Officer Jaideep Gogtay said the partnership reinforces the company's ongoing commitment to HIV/AIDS treatment, making life-saving drugs accessible.
 
"Raltegravir, a third line therapy treatment will be a value addition to Cipla's portfolio of HIV/AIDS treatment, especially for those patients who are resistant to the first and second line therapy treatments," he added.
 
Cipla MD and Global CEO Subhanu Saxena said by entering into the partnership with MSD, Cipla is demonstrating its commitment to working with partners globally who share the same pro-access philosophy of Cipla.
 
"We want to ensure that all patients, particularly in developing countries, get access to the most innovative, breakthrough medicines available," he added.
 
The total number of people living with HIV/AIDS (PLHIV) in India is estimated at around 20.9 lakh in 2011. It is estimated that about 1.48 lakh people died of AIDS related causes in 2011 in India.
 
-------------------------------------
 
http://www.businessweek.com/news/2014-01-21/merck-to-bristol-myers-face-more-threats-on-india-drug-patents
 
----------------------------------------
 
Merck Ties Up With Cipla To Sell HIV Drug In India
 
Feb 20 2014
http://www.businessworld.in
 
Cipla will have a non-exclusive license to market, promote and distribute MSD's raltegravir 400mg tablet, under a different brand name
 
P B Jayakumar
 
The US-based Merck & Co, (MSD), one of the largest multinational drug firms, has tied up with Indian drug major Cipla Ltd to sell its HIV drug raltegravir in India.
 
Cipla will have a non-exclusive license to market, promote and distribute MSD's raltegravir 400mg tablet, under a different brand name in India. Raltegravir is now approved in combination therapy in more than 76 countries for use in treatment-naïve adult patients with HIV-1 and in more than 114 countries for use in treatment-experienced adult patients with HIV-1.
 
Merck has a product patent for the drug in India since February 2008. The Chennai patent office had allowed the application filed in 2004. The US FDA allowed sale of this drug in 2007. Globally the drug is sold as Isentress. Global sales of the drug in 2012 were $1.5 billion, an 11 per cent increase over the previous year.
 
Interestingly, in April 2011,Cipla had moved an application to issue a compulsory license for the drug in India, citing the drug is overpriced and not affordable for Indian patients. Following Maraviroc and Etravirine, Raltegravir was the third granted a patent in India for the next- generation antiretrovirals.
 
"The deal demonstrates our commitment to working with partners globally who share the same pro access philosophy of Cipla. We want to ensure that all patients, particularly in developing countries, get access to the most innovative, breakthrough medicines available", said Subhanu Saxena, managing director and global CEO, Cipla.
 
The total number of people living with HIV/AIDS (PLHIV) in India is estimated at around 20.9 lakh in 2011.
 
"Raltegravir, a third line therapy treatment will be a value addition to Cipla's portfolio of HIV/AIDS treatment, especially for those patients who are resistant to the 1st and 2nd line therapy treatment", said Jaideep Gogtay, Chief Medical Officer, Cipla, announcing the tie-up.
 
"This partnership is aligned with our commitment towards patients in India and also addressing treatment challenges for high risk patients by providing broader access to our innovative medicines and vaccines", said K. G. Ananthakrishnan, Managing Director, MSD in India.
 
In July last year, MSD had entered into a similar alliance with Lupin to co-market a vaccine to prevent pneumonia. Similarly, MSD had tied up with Sun Pharma in 2011 to co-market MSD's diabetes drugs in India.
 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org